Фулвестрант Тева

Фулвестрант Тева is an intramuscular estrogen receptor antagonist used in hormone receptor-positive breast cancer therapy. This EU-sourced treatment provides targeted endocrine support for postmenopausal women. Fulvestrant Teva is prescribed under medical supervision for advanced or metastatic conditions.

Fulvestrant Teva is prescribed for hormone receptor-positive metastatic breast cancer in postmenopausal women. It is used when prior endocrine therapy has not controlled disease progression. The medication works by blocking estrogen receptors, slowing tumor growth. It may also be used in combination with targeted therapies as directed by a healthcare provider.

Fulvestrant Teva helps slow the spread of hormone-sensitive breast cancer by interfering with estrogen activity in tumor cells. Patients may experience improved symptom control and disease stabilization over time. Regular monitoring is required to assess treatment response and adjust care plans accordingly.

Fulvestrant Teva requires administration by a healthcare professional due to its intramuscular route. Patients should report any signs of allergic reactions, injection site reactions, or worsening symptoms immediately. Liver function tests are typically monitored during therapy. Use during pregnancy is contraindicated.

Fulvestrant Teva may interact with drugs that affect liver enzymes, such as CYP3A4 inducers or inhibitors. Caution is advised when combining with anticoagulants or other hormonal therapies. Patients should inform their doctor about all medications, including over-the-counter and herbal products, before starting treatment.